Stargardt Disease 1 Clinical Trial
Official title:
A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
This study will be comprised of a Phase 1b part conducted in Japan and a Phase 2/3 part. The Phase 1b part of the study will be open-label and will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of daily doses of 5 mg tinlarebant, administered for 7 days, in Japanese subjects with Stargardt Disease (STGD1). The Phase 2/3 part of the study will be randomized, double masked, and placebo controlled to evaluate the safety, tolerability, and efficacy of daily doses of 5 mg tinlarebant, administered for 24 months, in subjects with STGD1. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04281732 -
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
|
||
| Recruiting |
NCT05258032 -
Structural and Functional Characterization of Rare Ocular Diseases
|
||
| Active, not recruiting |
NCT06300476 -
Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
| Completed |
NCT03297515 -
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
|
N/A | |
| Active, not recruiting |
NCT05244304 -
Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1
|
Phase 3 | |
| Enrolling by invitation |
NCT03772938 -
Stem Cells Therapy in Degenerative Diseases of the Retina
|
Phase 1 |